Stinging Ant Anaphylaxis: Advances in Diagnosis and Treatment
The Journal of Allergy and Clinical Immunology: In Practice · 2025
DOI: 10.1016/j.jaip.2024.07.014 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2025. Verfasst von Jeremy C McMurray und 4 weiteren Autor:innen. Beteiligte Einrichtung: Allergy & Immunology Service, Walter Reed National Military Medical Center, Bethesda, Md. Electronic address: jeremymcmurray.md@gmail.com. Hauptthemen laut MEDLINE: Anaphylaxis, Ants, Insect Bites and Stings, Ant Venoms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 184 Literaturangaben. Gefördert von: U.S. Department of Defense.
Abstract (Originalsprache)
Stinging ants represent a wide range of over 200 different species across the world, of which Solenopsis, Myrmecia, Pogonomyrmex, and Brachyponera genera account for a substantial economic and healthcare burden. S. invicta (red imported fire ant [IFA]) and M. pilosula (jack jumper ant [JJA]) are 2 species of high clinical importance, known to cause anaphylaxis in humans, with numerous reported fatalities. Diagnostic testing should be performed in patients with a history of a systemic reaction with skin testing and/or in vitro specific immunoglobulin E (IgE) testing. In vitro testing is commercially available for IFA through whole-body extract specific IgE and JJA venom-specific IgE, but not widely available for other stinging ant species. Commercial venom component testing for IFA and JJA is currently not available. Patients with a clinical history and positive specific IgE testing should undergo treatment with specific immunotherapy, which is currently available for IFA and JJA. Buildup may be performed using conventional, semi-rush, rush, or ultra-rush schedules with similar risk profiles for IFA. Optimal duration for whole=body extract immunotherapy for IFA and specific JJA venom immunotherapy is not well studied, but generally recommended for at least 3 to 5 years. Sting challenges are used in research settings, primarily to assess treatment efficacy of immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy & Immunology Service, Walter Reed National Military Medical Center, Bethesda, Md. Electronic address: jeremymcmurray.md@gmail.com.
- Allergy & Immunology Service, Wilford Hall Ambulatory Surgical Center, San Antonio, Texas.
- Department of Clinical Immunology and Allergy, Incorporating the Jack Jumper Allergy Program, Royal Hobart Hospital, Hobart, Tasmania, Australia; College of Health and Medicine, University of Tasmania, Hobart, Tasmania,…
- Department of Allergy and Immunology, University of Adelaide, Adelaide, South Australia, Australia.
Förderung
- U.S. Department of Defense
Zitieren
APA
McMurray, J. C., Adams, K. E., Wanandy, T., Le, A., & Heddle, R. J. (2025). Stinging Ant Anaphylaxis: Advances in Diagnosis and Treatment. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2024.07.014
Vancouver
McMurray JC, Adams KE, Wanandy T, Le A, Heddle RJ. Stinging Ant Anaphylaxis: Advances in Diagnosis and Treatment. The Journal of Allergy and Clinical Immunology: In Practice. 2025. doi:10.1016/j.jaip.2024.07.014
BibTeX
@article{McMurray2025,
author = {McMurray, Jeremy C and Adams, Karla E and Wanandy, Troy and Le, Adriana and Heddle, Robert J},
title = {Stinging Ant Anaphylaxis: Advances in Diagnosis and Treatment},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2025},
doi = {10.1016/j.jaip.2024.07.014}
}
EUVIMED